Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa D Aimone

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Bioorganic & Medicinal Chemistry|October 5, 2011
Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one groupKaren L Milkiewicz, Lisa D Aimone, Mark S Albom, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activityGregory R Ott, Rabindranath Tripathy, Mangeng Cheng, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 18, 2011
CEP-26401 (irdabisant), a potent and selective histamine H₃ receptor antagonist/inverse agonist with cognition-enhancing and wake-promoting activitiesRita Raddatz, Robert L Hudkins, Joanne R Mathiasen, et al.
Journal of Medicinal Chemistry|December 4, 2003
A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055Diane E Gingrich, Dandu R Reddy, Mohamed A Iqbal, et al.
Journal of Medicinal Chemistry|December 14, 2011
Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agentRobert L Hudkins, Nadine C Becknell, Allison L Zulli, et al.
Bioorganic & Medicinal Chemistry Letters|February 7, 2015
Piperidine-3,4-diol and piperidine-3-ol derivatives of pyrrolo[2,1-f][1,2,4]triazine as inhibitors of anaplastic lymphoma kinaseEugen F Mesaros, Thelma S Angeles, Mark S Albom, et al.
Bioorganic & Medicinal Chemistry Letters|November 16, 2010
Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse modelsEugen F Mesaros, Jason P Burke, Jonathan D Parrish, et al.
Bioorganic & Medicinal Chemistry Letters|July 26, 2011
Identification of pyridazin-3-one derivatives as potent, selective histamine H₃ receptor inverse agonists with robust wake activityRobert L Hudkins, Lisa D Aimone, Thomas R Bailey, et al.
Journal of Medicinal Chemistry|May 9, 2012
Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinaseDiane E Gingrich, Joseph G Lisko, Matthew A Curry, et al.
Journal of Medicinal Chemistry|August 24, 2011
2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activityGregory R Ott, Gregory J Wells, Tho V Thieu, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Bioorganic & Medicinal Chemistry|October 5, 2011
Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one groupKaren L Milkiewicz, Lisa D Aimone, Mark S Albom, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activityGregory R Ott, Rabindranath Tripathy, Mangeng Cheng, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 18, 2011
CEP-26401 (irdabisant), a potent and selective histamine H₃ receptor antagonist/inverse agonist with cognition-enhancing and wake-promoting activitiesRita Raddatz, Robert L Hudkins, Joanne R Mathiasen, et al.
Journal of Medicinal Chemistry|December 4, 2003
A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055Diane E Gingrich, Dandu R Reddy, Mohamed A Iqbal, et al.
Journal of Medicinal Chemistry|December 14, 2011
Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agentRobert L Hudkins, Nadine C Becknell, Allison L Zulli, et al.
Bioorganic & Medicinal Chemistry Letters|February 7, 2015
Piperidine-3,4-diol and piperidine-3-ol derivatives of pyrrolo[2,1-f][1,2,4]triazine as inhibitors of anaplastic lymphoma kinaseEugen F Mesaros, Thelma S Angeles, Mark S Albom, et al.
Bioorganic & Medicinal Chemistry Letters|November 16, 2010
Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse modelsEugen F Mesaros, Jason P Burke, Jonathan D Parrish, et al.
Bioorganic & Medicinal Chemistry Letters|July 26, 2011
Identification of pyridazin-3-one derivatives as potent, selective histamine H₃ receptor inverse agonists with robust wake activityRobert L Hudkins, Lisa D Aimone, Thomas R Bailey, et al.
Journal of Medicinal Chemistry|May 9, 2012
Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinaseDiane E Gingrich, Joseph G Lisko, Matthew A Curry, et al.
Journal of Medicinal Chemistry|August 24, 2011
2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activityGregory R Ott, Gregory J Wells, Tho V Thieu, et al.
Pageof 5